Medical - Devices · NYSE
Current Price
$99.94
PE Ratio (TTM)
24.5x
Intrinsic Value
$110.94
+9.9% margin of safety
COMPETITIVE MOAT
↑Established Product Portfolio & Brand Recognition
Medtronic boasts a broad and diversified portfolio of medical devices, fostering strong brand recognition and trust among healthcare providers globally. This established presence creates significant barriers to entry for new competitors.
↑Regulatory Expertise & Approvals
Navigating complex regulatory pathways for medical devices is a significant hurdle. Medtronic's extensive experience and success in obtaining FDA and other global approvals provide a durable advantage.
↑Sales & Distribution Network
A vast and entrenched global sales and distribution network allows Medtronic to reach a wide customer base efficiently. This infrastructure is difficult and costly for rivals to replicate.
INVESTMENT RISKS
↓Product Recalls & Litigation
The nature of medical devices means that product recalls or litigation related to device malfunctions can significantly impact reputation and financial performance.
↓Healthcare Policy & Reimbursement Changes
Changes in government healthcare policies, reimbursement rates, and payer negotiations can directly affect Medtronic's revenue streams and profitability.
↓Integration of Acquisitions & Spinoffs
While strategic, integrating acquired companies or managing the complexities of spinoffs like the recent diabetes segment divestiture can present operational challenges and integration risks.
Base case
At a current price of $99.94, the base case PE valuation puts MDT fair value near $110.94 per share. That figure assumes 8.1% yearly earnings growth, a target PE multiple of 24.44x, and a 10% discount rate.
Intrinsic Value
$110.94
Margin of safety
+9.9%
Expected annual return
+2.1%
Base case assumptions: 8.1% annual earnings growth, 24.44x target PE, 10% discount rate, 5 year projection. Data as of 2026-11-20.
This base case uses default assumptions and is not financial advice. The fair value changes significantly when the target PE or earnings growth rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Adjust the target PE, earnings growth, and discount rate to see how the fair value and margin of safety for Medtronic Plc respond.
Open PE Calculator for MDTMedtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
PE Ratio (TTM)
24.5x
PEG Ratio
1.98
Earnings Yield
4.09%
ROE (TTM)
10.6%
Revenue/Share (TTM)
$29.33
Dividend Yield
2.86%
Debt/Equity
0.56x
The trailing twelve-month PE ratio of MDT reflects how much investors pay per dollar of Medtronic Plc's earnings. This metric is most useful when compared to Medical - Devices peers and the company's own historical range.
MDT's PE of 24.5x combined with a PEG ratio of 1.98 provides a growth-adjusted perspective. A PEG near 1.0 means the P/E is roughly in line with the earnings growth rate. Keep in mind that PE-based valuation works best for profitable, mature companies — for high-growth or cyclical Medical - Devices, a DCF analysis may be more appropriate.
To value Medtronic Plc using PE: (1) Compare the current PE (24.5x) against the Medical - Devices median to assess relative pricing, (2) check the PEG ratio (1.98) to adjust for growth expectations, (3) review the 5-year PE range to identify where the stock sits historically, and (4) estimate fair value by multiplying a target PE by forward EPS estimates. This relative approach complements DCF's absolute valuation.
MDT's PEG ratio is 1.98, calculated by dividing the PE ratio (24.5x) by the expected earnings growth rate. A PEG near 1.0 means the P/E is roughly in line with the expected earnings growth rate. Note that PEG accuracy depends on the reliability of growth estimates.
PE ratio gives a quick relative read — how MDT is priced versus Medical - Devices peers. DCF provides an absolute value based on projected free cash flows. For the most reliable valuation, use PE as a quick comparability screen and DCF for a deeper fundamental analysis. Each method has blind spots: PE ignores capital structure and cash flow quality, while DCF is sensitive to growth and discount rate assumptions.
P/E and DCF value MDT with different methods and assumptions, so the two conclusions can differ. Compare the DCF intrinsic value.
Price as of 2026-11-20. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.